Revolution Medicines (RVMD) Corporate presentation summary

Clinical milestones and pipeline progress

• Achieved unprecedented overall survival benefit in the RASolute 302 Phase 3 trial for daraxonrasib in metastatic pancreatic cancer, with a 60% reduction in risk of death and median OS over one year compared to chemotherapy.

• Preparing NDA submission for daraxonrasib as the first step in global registration, with ongoing and planned Phase 3 trials across multiple tumor types and treatment lines.

• Pipeline includes four clinical-stage RAS(ON) inhibitors (daraxonrasib, zoldonrasib, elironrasib, RMC-5127) and additional preclinical assets targeting diverse RAS mutations.

• Robust development programs for pancreatic, non-small cell lung, and colorectal cancers, with eight randomized Phase 3 registrational trials active or planned for 2026.

Key clinical data highlights

• Daraxonrasib demonstrated statistically significant improvements in progression-free and overall survival in previously treated metastatic pancreatic cancer, with a manageable safety profile.

• In first-line pancreatic cancer, daraxonrasib monotherapy and combination with GnP showed high response and disease control rates, with favorable tolerability.

• Zoldonrasib monotherapy in KRAS G12D NSCLC showed a 52% ORR and 93% DCR, with encouraging durability and safety.

• Elironrasib demonstrated antitumor activity in G12C NSCLC, including in patients previously treated with G12C (OFF) inhibitors.

Strategic and operational advancements

• Expanding commercialization capabilities, scaling organization for daraxonrasib launch, and building presence in priority international regions.

• Strong financial position with $1.9B in cash and investments as of March 2026, $2.4B in net proceeds from April 2026 financing, and $2B in committed capital from Royalty Pharma.

• Industry-leading discovery platform focused on RAS(ON) inhibitors, with continuous innovation and investment in novel targeted therapies.